Most Read Articles
Roshini Claire Anthony, 25 Jun 2020

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.

Ms Penny Wong Pei Nee, 12 Jul 2018
Antibiotics, also known as antibacterials, are a group of medications that either destroy the infecting bacteria or slow down their growth.
Elaine Soliven, 30 Jun 2020
Treatment with Lactobacillus crispatus CTV-05 (Lactin-V) significantly reduces the incidence of bacterial vaginosis recurrence in women who were previously treated with vaginal metronidazole, according to a recent study.
Elaine Soliven, 20 Jun 2020
SNF472 treatment resulted in a significantly slower progression of coronary artery calcium (CAC) in patients with end-stage renal disease (ESRD) receiving haemodialysis, according to a prespecified subgroup analysis of the CaLIPSO* study presented at ERA-EDTA 2020.

Product Highlight – Dukoral

12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics

The Drinkable Vaccine against Cholera & enterotoxigenic E.coli (ETEC) Diarrhoea


Clinically proven protective efficacy:
- Up to 85-90% against cholera in the first 6 months3,4,6
- Up to 67% against ETEC in the first 3 months.5

At least one week interval between doses. Primary immunization can be completed as early as 8 days for adults and children over 6 years old (2 required doses) and 15 days for children 2-6 years (3 required doses).1

Onset of protection starts 7 days after completion of immunisation. The vaccination course should be completed at least one week before traveling.1

Good safety profile with most frequently reported adverse reactions occurred at similar frequencies in vaccine and placebo group in studies.

References:

1. DUKORAL full prescribing information (SV40398_MY).
2. Clements JD, Finkelstein RA. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun 1978;22:709–13.
3. World Health Organization. Use of Oral Cholera Vaccine in Humanitarian Emergencies. http://www.who.int/cholera/vaccines/OCV_in_humanitarian_emergencies_15Jan2014.pdf.
4. Clemens JD, Sack DA, Harris RJ et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-7.
5. Clemens JD., et al. Cross-protection by B subunit whole-cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: result of a large-scale field trial. J Infect Dis 1988; 158:372-77.
6.
World Health Organization. Cholera vaccines WHO position paper. Weekly Epidemiologic Record (WER). No 13, 2010, 85, 117-128 http://www.who.int/wer/2010/wer8513.pdf.

Further information is available in section 12b, New in This Issue and mims.com
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 25 Jun 2020

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.

Ms Penny Wong Pei Nee, 12 Jul 2018
Antibiotics, also known as antibacterials, are a group of medications that either destroy the infecting bacteria or slow down their growth.
Elaine Soliven, 30 Jun 2020
Treatment with Lactobacillus crispatus CTV-05 (Lactin-V) significantly reduces the incidence of bacterial vaginosis recurrence in women who were previously treated with vaginal metronidazole, according to a recent study.
Elaine Soliven, 20 Jun 2020
SNF472 treatment resulted in a significantly slower progression of coronary artery calcium (CAC) in patients with end-stage renal disease (ESRD) receiving haemodialysis, according to a prespecified subgroup analysis of the CaLIPSO* study presented at ERA-EDTA 2020.